Sun Yat-Sen Memorial Hospital
Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China18 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab | Euthyroid With Thyroid Antibodies; Recurrent Pregnancy Loss | Recruiting | Not applicable | 2026-09-30 | NCT06652113 | |
| Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma | Disease Attributes, Disease Progression, Head and Neck Neoplasms, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, head and neck cancer, neoplasm | Recruiting | Not stated | 2026-08-31 | NCT06755567 | |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bladder transitional cell carcinoma, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-07-21 | NCT07717242 | |
| Study of YK012 in B-cell Acute Lymphoblastic Leukemia | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-02-06 | NCT06580301 | |
| Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005） | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2025-12-05 | NCT07267286 | |
| DCNN Developed for Detection and Assessing the Perfusion of PTG | Thyroidectomy | Recruiting | Not stated | 2025-12-03 | NCT05869058 | |
| PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Not yet recruiting | Phase 2 | 2025-07-29 | NCT07090707 | |
| Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2024-09-19 | NCT05724329 | |
| Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Oral Squamous Cell Carcinoma, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, oropharynx squamous cell carcinoma, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2024-09-19 | NCT04718415 | |
| Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Oral Squamous Cell Carcinoma, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, oropharynx squamous cell carcinoma, squamous cell carcinoma | Recruiting | Phase 2 | 2024-03-26 | NCT05098119 | |
| A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2024-02-07 | NCT05678270 | |
| Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Site, Stomatognathic Diseases, mouth disorder, neoplasm | Recruiting | Phase 2 | 2023-11-14 | NCT06130332 | |
| 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, mouth disorder, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2023-09-07 | NCT05980702 | |
| PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 3 | 2023-08-08 | NCT05980715 | |
| A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2023-04-14 | NCT04992559 | |
| Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2023-04-14 | NCT04807140 | |
| Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | Salivary Gland Malignant Neoplasms; Salivary Gland Tumors | Recruiting | Phase 2 | 2022-12-02 | NCT05000892 | |
| Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | Salivary Gland Malignant Neoplasms; Salivary Gland Tumors | Not yet recruiting | Phase 2 | 2021-04-28 | NCT04825938 |